Clinical Trial Update: Study of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) Without the 5q Deletion and Transfusion Dependent Anaemia [Phase 2]

View source ↗

Summary

Phase 2 study comparing azacitidine (Vidaza) to best supportive care in low-risk myelodysplastic syndrome patients without 5q deletion and with transfusion-depe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• VIDAZA (AZACITIDINE)

Snippet

Sponsor: Asociación Andaluza de Hematología y Hemoterapia | Conditions: Myelodysplastic Syndrome (MDS) | Phase 2 | Status: COMPLETED